FDA panel endorses drug for vitreomacular adhesion

WASHINGTON (Reuters) - A Food and Drug Administration panel on Thursday recommended ThromboGenics NV's ocriplasmin as a treatment for vitreomacular adhesion, an aging-related vision problem that can lead to blindness.

Full Story →